|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we used two cytostatic agents used in melanoma therapies in combination with PARP inhibition to have an insight into cellular events using the B16F10 melanoma model.
|
31133874 |
2019 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that 2HF-PLO gel maybe useful for topical therapy of cutaneous metastases of melanoma and could enhance theantineoplastic effects of sunitinib and PARP1 inhibitors.
|
31615091 |
2019 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To do so, an A375 dabrafenib-resistant (A375DR) melanoma cell subpopulation was selected and its behavior compared with that of parental (A375P) cells by crystal violet, 5-Bromo-2'-deoxyuridine incorporation, and cleaved poly(ADP-ribose) polymerase 1 (PARP1) western blot measurements.
|
31783660 |
2019 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Expression quantitative trait locus (eQTL) analysis in multiple cell types of the melanocytic lineage consistently demonstrated that the 1q42.1 melanoma risk allele (rs3219090[G]) is correlated with higher PARP1 levels.
|
28759004 |
2017 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Expression quantitative trait locus (eQTL) analysis in multiple cell types of the melanocytic lineage consistently demonstrated that the 1q42.1 melanoma risk allele (rs3219090[G]) is correlated with higher PARP1 levels.
|
28759004 |
2017 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The expression of cleaved forms of caspase-3 and poly(ADP-ribose) polymerase-1 (PARP-1) suggested that the extract induced apoptosis through caspase-3 activation in both human malignant melanoma (SK-Mel-28) and human cervical cancer (HeLa) cell lines.
|
28208804 |
2017 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, we identified several rare CNVs that either involved known melanoma genes (e.g., PARP1, CDKN2A) or cosegregated with melanoma (duplication on 10q23.23, 3p12.2 and deletions on 8q424.3, 2q22.1) in families without mutations in known melanoma high-risk genes.
|
27476724 |
2016 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This work for the first time demonstrates the effectiveness of a combination of PARP1 inhibitor olaparib and alkylating agent DTIC for treating LIG4 deficient melanomas.
|
27705909 |
2016 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our study shows that XPA can promote cell-protective autophagy in a DNA repair-independent manner by enhancing the activation of PARP1 in melanoma cells resistant to cisplatin and that the XPA-PARP1-mediated autophagy process can be targeted to overcome cisplatin resistance in melanoma chemotherapy.
|
26880244 |
2016 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Eleven SNPs in 6 gene neighborhoods (TERT/CLPTM1L, TYRP1, MTAP, TYR, NCOA6, and MX2) and a PARP1 haplotype were associated with multiple primary melanoma.
|
25837821 |
2015 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Evidence for a role of the PARP1 protein in melanoma ulceration and survival was investigated by testing gene expression levels taken from formalin-fixed paraffin-embedded tumors.
|
24535833 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We confirm the protective role in MM of the rs3219090 located on the PARP1 gene (p-value 0.027).
|
23537197 |
2013 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Sensitivity of melanoma cells to cis-diaminedichloroplatinum II (cDDP, cis-platin), carboplatin, dacarbazine, or temozolomide together with velaparib, an inhibitor of poly (ADP ribose) polymerase 1, is increased by up to 10-fold by targeting genes that regulate both protein trafficking and the formation of melanosomes, intracellular organelles unique to melanocytes and melanoma cells.
|
22203954 |
2012 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.
|
21983785 |
2011 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.
|
21983785 |
2011 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest the possible involvement of the PARP1 variant in melanoma development, especially for sites with high sun exposure.
|
20837404 |
2011 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Silencing of PARP-1 in melanoma or cervical carcinoma lines enhanced in vitro sensitivity to TMZ and Me- Lex, and induced a higher level of cell accumulation at the G2/M phase of cell cycle with respect to controls.
|
20464779 |
2010 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In a hospital-based case-control study of 602 CM patients and 603 cancer-free control subjects frequency matched on age, sex and ethnicity, we genotyped for three non-synonymous single nucleotide polymorphisms (SNPs) (i.e. the ADPRT Val762Ala, XRCC1 Arg399Gln and APE1Asp148Glu) and assessed their associations with risk of CM.
|
16621887 |
2006 |